Telomir Pharmaceuticals (NASDAQ:TELO) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Telomir Pharmaceuticals (NASDAQ:TELO) from a sell rating to a hold rating in a research report report published on Saturday morning.

Several other equities research analysts also recently weighed in on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Telomir Pharmaceuticals in a research note on Thursday, January 22nd. Rodman & Renshaw started coverage on Telomir Pharmaceuticals in a research note on Tuesday, January 13th. They issued a “buy” rating for the company. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold”.

Telomir Pharmaceuticals Stock Performance

NASDAQ:TELO opened at $1.14 on Friday. The firm has a 50-day simple moving average of $1.29 and a 200-day simple moving average of $1.39. Telomir Pharmaceuticals has a one year low of $1.05 and a one year high of $5.40. The firm has a market cap of $39.19 million, a P/E ratio of -3.08 and a beta of -0.49.

Hedge Funds Weigh In On Telomir Pharmaceuticals

A number of institutional investors have recently modified their holdings of TELO. Marshall Wace LLP acquired a new position in shares of Telomir Pharmaceuticals in the 2nd quarter valued at about $95,000. Raymond James Financial Inc. lifted its holdings in Telomir Pharmaceuticals by 4,101.9% in the third quarter. Raymond James Financial Inc. now owns 75,340 shares of the company’s stock valued at $105,000 after acquiring an additional 73,547 shares during the period. Y Intercept Hong Kong Ltd purchased a new stake in Telomir Pharmaceuticals in the 2nd quarter worth approximately $81,000. Jane Street Group LLC acquired a new stake in shares of Telomir Pharmaceuticals during the 2nd quarter worth approximately $62,000. Finally, XTX Topco Ltd purchased a new position in shares of Telomir Pharmaceuticals during the 4th quarter valued at approximately $53,000.

Telomir Pharmaceuticals Company Profile

Telomir Pharmaceuticals, Inc (NASDAQ: TELO) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapies for cardiometabolic and fibrotic diseases. Leveraging a proprietary target discovery platform, the company aims to identify and modulate key biological pathways implicated in tissue fibrosis, inflammation and metabolic dysregulation. Its research strategy centers on oral agents intended to address high-unmet-need conditions such as nonalcoholic steatohepatitis (NASH) and systemic fibrotic disorders, where existing treatment options are limited.

The company’s lead development candidate is an oral inhibitor currently in early-phase clinical trials that targets growth factors involved in fibrotic tissue remodeling.